Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980684 | 0.93 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1TP53BP1MEN1KMT2A | |
| SCHEMBL4974790 | 0.89 | HRH3 (0.48) | MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4981943 | 0.89 | MEN1 (0.55) | L3MBTL3L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL4083239 | 0.89 | HRH1 (0.47) | MEN1KMT2AHRH3HRH1MAPT | |
| SCHEMBL4980403 | 0.87 | MEN1 (0.41) | L3MBTL3L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL4978137 | 0.86 | MEN1 (0.43) | MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4978237 | 0.84 | MEN1 (0.43) | MEN1KMT2AHRH3HRH1MAPT | |
| SCHEMBL4977730 | 0.82 | PIK3CA (0.41) | L3MBTL3MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4977783 | 0.82 | TRPV6 (0.53) | MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4979114 | 0.82 | MEN1 (0.47) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | L3MBTL3 2564/4885L3MBTL1 2549/4885TP53BP1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.